Departments of Oncology, Surgery and Histopathology, Imperial College, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, UK.
J Clin Pathol. 2011 Sep;64(9):829-31. doi: 10.1136/jcp.2011.089433. Epub 2011 May 17.
The epidermal growth factor receptor (EGFR) is a therapeutic target in a number of settings in solid malignancies, but its role in breast cancer has remained unclear and controversial. In 810 primary breast cancers derived from patients suitable for cytotoxic chemotherapy, EGFR was prospectively measured and interactions with tumour and clinical correlates were tested to observe whether postulated cross-talk mechanisms are likely to modulate breast cancer metastasis and proliferation. A minority (79 tumours, 9.8%) were EGFR positive; in a multivariate analysis the likelihood of being EGFR positive was significantly increased for patients with grade 3 disease, compared with grade 1 (OR 15.6; 95% CI 2 to 122, p=0.0001), and for oestrogen receptor-negative status compared with positive (OR 24.1; 95% CI 12.7 to 46.00, p=0.0001). EGFR expression may play a role in breast cancer proliferation, but appears unlikely to modify tumour pathology via postulated mechanisms of oestrogen receptor/EGFR-mediated cross-talk.
表皮生长因子受体（EGFR）是许多实体恶性肿瘤中治疗的靶点，但它在乳腺癌中的作用仍不清楚且存在争议。在 810 例来自适合细胞毒性化疗的患者的原发性乳腺癌中，前瞻性地测量了 EGFR，并测试了与肿瘤和临床相关性的相互作用，以观察假定的串扰机制是否可能调节乳腺癌的转移和增殖。少数（79 例肿瘤，9.8%）为 EGFR 阳性；多变量分析显示，与 1 级（OR 15.6；95%CI 2 至 122，p=0.0001）相比，3 级疾病患者 EGFR 阳性的可能性显著增加，与雌激素受体阳性相比，EGFR 阳性（OR 24.1；95%CI 12.7 至 46.00，p=0.0001）。EGFR 表达可能在乳腺癌增殖中起作用，但通过假定的雌激素受体/EGFR 介导的串扰机制来改变肿瘤病理学的可能性似乎不大。
